Compare ACU & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | KRRO |
|---|---|---|
| Founded | 1867 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 150.0M |
| IPO Year | 1994 | 2019 |
| Metric | ACU | KRRO |
|---|---|---|
| Price | $45.63 | $13.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $50.00 | $34.80 |
| AVG Volume (30 Days) | 15.2K | ★ 171.5K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ 1.63 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $196,541,816.00 | $6,392,000.00 |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $5.19 | N/A |
| P/E Ratio | $18.48 | ★ N/A |
| Revenue Growth | 1.05 | ★ 181.46 |
| 52 Week Low | $35.50 | $5.20 |
| 52 Week High | $47.31 | $55.89 |
| Indicator | ACU | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 57.22 |
| Support Level | $40.48 | $12.98 |
| Resistance Level | $46.89 | $15.00 |
| Average True Range (ATR) | 1.34 | 1.02 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 65.97 | 50.34 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.